Trial Profile

Efficacy and safety of liraglutide versus lixisenatide as add-on to metformin in subjects with type 2 diabetes.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Liraglutide (Primary) ; Lixisenatide; Metformin
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms LIRA-LIXI
Sponsors Novo Nordisk

Most Recent Events

16 Jun 2016 Results published in the Diabetes Care
16 Sep 2015 According to Novo Nordisk media release, results were presented in an oral presentation at the 51st Annual Meeting of the European Association for the Study of Diabetes.
16 Sep 2015 Results published in Novo Nordisk media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com